scPharmaceuticals Inc. announced its financial results for the first quarter ended March 31, 2025, reporting net FUROSCIX revenue of $11.8 million. This represents a 93% increase compared to $6.1 million in the first quarter of 2024, driven by increased demand for FUROSCIX.
The company formally launched FUROSCIX in its second approved indication, chronic kidney disease, in April 2025. This expansion is a key component of scPharmaceuticals' long-term growth initiatives, with the sales force actively engaging nephrologists and reporting positive receptivity.
Despite a net loss of $19.7 million for the quarter, scPharmaceuticals noted that the Autoinjector remains on track for sNDA submission in Q3 2025, designed to reduce treatment time from five hours to less than ten seconds. The company also observed an acceleration in fill rates and prescription volumes starting in March and early Q2, attributing this to the Medicare Part D redesign and copay smoothing, which reduce patient out-of-pocket costs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.